BIOSTAX CORP - BTAX STOCK NEWS

Welcome to our dedicated page for BIOSTAX news (Ticker: BTAX), a resource for investors and traders seeking the latest updates and insights on BIOSTAX stock.

Biostax Corp (OTC Pink: BTAX) is a specialty pharmaceutical company focused on manufacturing, distributing, and marketing patented therapies to combat chronic, life-threatening diseases by modulating the immune system. Its technology platform includes low dose naltrexone (LDN) and methionine-enkephalin (MENK) developed over decades by leading institutions.

The company recently underwent a transformative rebranding initiative, changing its name from Immune Therapeutics, Inc. to Biostax, signaling a shift towards addressing substance abuse challenges globally. Biostax aims to provide evidence-based interventions and innovative HIV treatments to improve health outcomes. Its commitment to transparency and innovation positions Biostax as a leader in healthcare solutions.

11/30/2023 09:45 AM

News

Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception

Rhea-AI Summary

Biostax Corp. (BTAX) proudly announces its participation in the U.S. Business Action to End HIV Annual Coalition Meeting and the World AIDS Day Reception. The company's commitment to driving accelerated progress toward ending HIV is evident through its collaboration, innovation, and collective efforts. The expanded board brings fresh perspectives and strategic insights, unlocking new opportunities for Biostax Corp. to contribute significantly to the global effort against HIV.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-14.29%

Tags

11/15/2023 09:30 AM

News

Biostax Announces a Director Appointment of Influential Business Leader Craig Suro

Rhea-AI Summary

Biostax Corp (BTAX) announces the appointment of Influential Business Leader Roger “Craig” Suro, a renowned Virginia native with a track record in business innovation, public policy, and community revitalization. Mr. Suro's expertise in driving capital, innovation, and funding for transformative projects is expected to amplify Biostax's growth trajectory, bringing unparalleled opportunities and increased funding avenues.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

15%

Tags

11/02/2023 10:10 AM

News

Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors

Rhea-AI Summary

Biostax Corp announces the appointment of Clay Caperton to its Board of Directors. Caperton has a rich history in sports management and the not-for-profit sector. She has a track record of securing substantial financial contributions and cultivating donor networks. Biostax expects her to enhance fundraising initiatives and foster valuable relationships for unprecedented growth and impact.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/24/2023 09:15 AM

News

Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment

Rhea-AI Summary

Biostax Corp announces milestone in rebranding initiative, changes name to Biostax and ticker symbol to BTAX. Company focuses on substance abuse solutions and HIV treatment, aiming to address global challenges and improve health outcomes.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.15%

Tags

FAQ

What is the current stock price of BIOSTAX (BTAX)?

The current stock price of BIOSTAX (BTAX) is $0.035 as of May 29, 2024.

What is the market cap of BIOSTAX (BTAX)?

The market cap of BIOSTAX (BTAX) is approximately 4.0M.

What is Biostax Corp (BTAX) focused on?

Biostax Corp specializes in manufacturing, distributing, and marketing patented therapies to combat chronic, life-threatening diseases through immune modulation.

What are the key technologies in Biostax's platform?

Biostax's technology platform includes two immunotherapies, low dose naltrexone (LDN) and methionine-enkephalin (MENK), developed by renowned institutions.

What recent milestone did Biostax achieve?

Biostax recently rebranded from Immune Therapeutics, Inc. to Biostax, signaling a strategic shift towards addressing substance abuse challenges and advancing HIV treatment.

How does Biostax aim to make an impact globally?

Biostax aims to provide evidence-based interventions and collaborate with international partners to offer comprehensive solutions for substance abuse and innovative treatments for HIV.

Who leads Biostax Corp?

Biostax is led by CEO Noreen Griffin, who is dedicated to positioning the company as a leader in healthcare solutions and addressing global healthcare challenges.